Access HBV Assays - European Union (EU) Clinical Trial Protocol -

RecruitingOBSERVATIONAL
Enrollment

21,210

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
HBV
Interventions
DIAGNOSTIC_TEST

Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays

All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.

Trial Locations (5)

76031

RECRUITING

Laboratoire de Virologie, Laboratoire associé au CNR du VIH Institut de Biologie Clinique ; hôpital C : Nicolle, CHU Rouen, Rouen

76232

NOT_YET_RECRUITING

Etablissement Français du Sang (EFS) Hauts-de-France - Normandie, Bois-Guillaume

80054

RECRUITING

Centre de Ressources Biologiques Biobanque de Picardie CHU Amiens-Picardie, Amiens

94208

RECRUITING

Eurofins Biomnis, Ivry-sur-Seine

95310

RECRUITING

Cerba Xpert, Saint-Ouen-l'Aumône

Sponsors
All Listed Sponsors
lead

Beckman Coulter, Inc.

INDUSTRY

NCT04904835 - Access HBV Assays - European Union (EU) Clinical Trial Protocol - | Biotech Hunter | Biotech Hunter